The ESC/EACT guidelines on valvular heart disease include substantial new trial evidence and diverge on intervention thresholds compared to ACC/AHA guidelines.
Absolute Event Rate: 0% vs 0%
Abstract Valvular heart disease poses persistent challenges for clinical decision-making, and international guidelines provide essential frameworks for its management. The American College of Cardiology/American Heart Association last issued a full update in 2020 and an expert consensus on tricuspid regurgitation in 2025. The European Society of Cardiology/European Association for Cardio-Thoracic Surgery released their updated guidelines in 2025. Although there is broad alignment in principles of intervention, prosthesis choice, and the role of Heart Teams, the European document incorporates substantial new trial evidence. Key areas of divergence include thresholds for earlier intervention in aortic stenosis and regurgitation, expanded recommendations for transcatheter edge-to-edge repair and mitral replacement, formal integration of tricuspid repair and transcatheter therapies, evolving strategies for coronary assessment in transcatheter aortic valve implantation, and sex-specific considerations. This review highlights consistencies, discrepancies, and priorities for future research.
Dębski et al. (Fri,) reported a other. The ESC/EACT guidelines on valvular heart disease include substantial new trial evidence and diverge on intervention thresholds compared to ACC/AHA guidelines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: